January 4, 2019

Amring Pharmaceuticals Inc. (Amring), a generic pharmaceutical and ophthalmic medical device company, announced today that it launched a generic oncology drug, Arsenic Trioxide Injection in November 2018 and expects to launch four (4) additional generic drugs in 2019. These five (5) drugs are distributed to the retail, hospital, and institutional channels and allow Amring to continue adding value to its customers and patients.
Read more

Amring
Products Partner Company LinkedIn
More news & events